Free Access
Med Sci (Paris)
Volume 23, Number 4, Avril 2007
Page(s) 423 - 427
Section M/S revues
Published online 15 April 2007
  1. Lowy DR, Howley PH. Papillomaviruses. In : Knipe DM, Howley PH, eds. Fields virology. Philadelphia, Pennsylvania, USA : Lippincott, Williams and Wilkins, 2001 : 2231–64. [Google Scholar]
  2. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348 : 518–27. [Google Scholar]
  3. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen ? The international perspective. Int J Cancer 2004; 111 : 278–85. [Google Scholar]
  4. Peto J, Gilham C, Deacon J, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2004; 91 : 942–53. [Google Scholar]
  5. Yang BH, Bray FI, Parkin DM, et al. Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer 2004; 109 : 418–24. [Google Scholar]
  6. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189 : 12–9. [Google Scholar]
  7. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991; 185 : 251–7. [Google Scholar]
  8. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women : a randomised controlled trial. Lancet 2004; 364 : 1757–65. [Google Scholar]
  9. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347 : 1645–51. [Google Scholar]
  10. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6 : 271–8. [Google Scholar]
  11. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006; 107 : 18–27. [Google Scholar]
  12. Rose RC, Reichman RC, Bonnez W. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol 1994; 75 : 2075–9. [Google Scholar]
  13. Roden RB, Hubbert NL, Kirnbauer R, et al. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol 1996; 70 : 3298–301. [Google Scholar]
  14. Koutsky LA, Harper DM. Current findings from prophylactic HPV vaccine trials. Vaccine 2006; 24 (suppl 3) : S114–21. [Google Scholar]
  15. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18 : follow-up from a randomised control trial. Lancet 2006; 367 : 1247–55. [Google Scholar]
  16. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95 : 1459–66. [Google Scholar]
  17. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118 : 2135–45. [Google Scholar]
  18. Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 2006; 24 : 5571–83. [Google Scholar]
  19. Poland GA, Jacobson RM, Koutsky LA, et al. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16 : a 2-year randomized controlled clinical trial. Mayo Clin Proc 2005; 80 : 601–10. [Google Scholar]
  20. Grunbaum JA, Kann L, Kinchen S, et al. Youth risk behavior surveillance: United States, 2003. MMWR Surveill Summ 2004; 53 : 1–96. [Google Scholar]
  21. Winer RL, Lee SK, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157 : 218–26. [Google Scholar]
  22. Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 2002; 13 : 631–9. [Google Scholar]
  23. Hawes SE, Critchlow CW, Faye Niang MA, et al. Increased risk of high-grade cervical squamous intraepithelial lesions and invasive cervical cancer among African women with human immunodeficiency virus type 1 and 2 infections. J Infect Dis 2003; 188 : 555–63. [Google Scholar]
  24. Weller TH. Serial propagation in vitro of agents producing inclusion bodies derived from varicella and herpes zoster. Proc Soc Exp Biol Med 1953; 83 : 340–6. [Google Scholar]
  25. Preblud SR, Orenstein WA, Bart KJ. Varicella: clinical manifestations, epidemiology, and health impact in children. Pediatr Infect Dis 1984; 3 : 505–9. [Google Scholar]
  26. Leclair JM, Zaia JM, Levin MJ, et al. Airborne transmission of chickenpox in a hospital. N Engl J Med 1980; 302 : 450–3. [Google Scholar]
  27. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965; 58 : 9–20. [Google Scholar]
  28. Gershon A, Steinberg S, Borkowsky W, et al. Subclinical zoster: identification by serum IgM to varicella-zoster virus. Pediatr Res 1981; 15 : 610. [Google Scholar]
  29. Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002; 347 : 340–6. [Google Scholar]
  30. Oxman MN. Clinical manifestations of herpes zoster. In : Arvin AM, Gershon AA, eds. Varicella zoster virus : virology and clinical management. Cambridge, England : Cambridge University Press, 2000 : 246–75. [Google Scholar]
  31. Ragozzino MW, Melton LJ, Kurland LT, et al. Population-based study of herpes zoster and its sequelae. Medicine 1982; 61 : 310–6. [Google Scholar]
  32. Jung BF, Johnson RW, Griffin DR, Dworkin RH. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004; 62 : 1545–51. [Google Scholar]
  33. D workin RH, Schmader KE. The treatment and prevention of postherpetic neuralgia. Clin Infect Dis 2003; 36 : 877–82. [Google Scholar]
  34. Kost RG, Straus SE. Postherpetic neuralgia: pathogenesis, treatment, and prevention. N Engl J Med 1996; 335 : 32–42. [Google Scholar]
  35. Buchbinder SP, Katz MH, Hessol NA, et al. Herpes zoster and human immunodeficiency virus infection. J lnfect Dis 1992; 166 : 1153–6. [Google Scholar]
  36. Weller TH. Varicella and herpes zoster : changing concepts of the natural history, control and importance of a not-so-benign virus (part two). N Engl J Med 1983; 309 : 1434–40. [Google Scholar]
  37. Glesby MJ, Moore RD, Chaisson RE. Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. Clin Infect Dis 1995; 21 : 370–5. [Google Scholar]
  38. Takahashi M, Otsuka T, Okuno Y, et al. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974; 2 : 1288–90. [Google Scholar]
  39. Hambleton S, Gershon AA. Preventing varicella-zoster disease. Clin Microbiol Rev 2005; 18 : 70–80. [Google Scholar]
  40. Sharrar RG, LaRussa P, Galea S, et al. The postmarketing safety profile of varicella. Vaccine 2001; 19 : 916–23. [Google Scholar]
  41. Vazquez M, LaRussa P, Gershon A, et al. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 2001; 344 : 955–60. [Google Scholar]
  42. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352 : 2271–84. [Google Scholar]
  43. Tyring SK, Diaz-Mitoma F, Padget LG, et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥50 years of age. Vaccine 2007; 25 : 1877–83. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.